Abstract
The prognostic value of c-erbB-2 oncogene expression was studied retrospectively in a consecutive series of 230 node negative breast cancers, followed-up for at least 7 years after primary treatment. The expression of c-erbB-2 oncoprotein was determined on formalin-fixed paraffin-embedded tissue, using a monoclonal anti-c-erbB-2 antibody by the avidin-biotin immunoperoxidase method. Positive immunostaining was observed in 20.9% of cases, whereas strong diffuse positivity was recorded only in 8.7% of cases. C-erbB-2 gene product showed no association to T category or nuclear grade. A significant association of c-erbB-2 expression to prognosis was observed only for cases showing a strong diffuse immunostaining, but such an association was no longer statistically significant at multivariate analysis adjusting for other prognostic factors such as T category and nuclear grading. C-erbB-2 expression is of no value to predict the clinical course of node negative patients in the current practice.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bianchi, S., Paglierani, M., Zampi, G. et al. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer 67, 625–629 (1993). https://doi.org/10.1038/bjc.1993.114
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.114
- Springer Nature Limited
This article is cited by
-
Measurement of HER2 in Saliva of Women in Risk of Breast Cancer
Pathology & Oncology Research (2013)
-
Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate
Medical Oncology (2011)
-
Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer
Journal of Cancer Research and Clinical Oncology (1995)